Skip to main content

Table 1 Variations in glycans determined through lectin microarray analysis of the A2780 cells and A2780-cp cells

From: Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp

No. Lectin Preferred glycan structure (terminal epitope) A2780-1 ± SD CP-1 ± SD C1/A1 A2780-2 ± SD CP-2 ± SD C2/A2
1 LTL Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc 0.58 ± 0.02 0.62 ± 0.01 1.07** 0.47 ± 0.02 0.41 ± 0.02 0.86*
2 PSA Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.90 ± 0.03 1.06 ± 0.02 1.17*** 0.94 ± 0.04 1.05 ± 0.07 1.11
3 LCAa Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.86 ± 0.04 0.99 ± 0.03 1.15*** 1.02 ± 0.02 1.21 ± 0.08 1.19**
4 UEA-I Fuc α1-2(Gal β1-4)GlcNAc 0.43 ± 0.02 0.52 ± 0.02 1.20*** 0.48 ± 0.01 0.34 ± 0.00 0.71***
5 AOLa Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc 0.49 ± 0.02 0.47 ± 0.01 0.96*** 0.52 ± 0.03 0.46 ± 0.02 0.87*
6 AAL Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex) 0.80 ± 0.03 0.86 ± 0.04 1.07*** 1.04 ± 0.09 0.78 ± 0.02 0.76*
7 MAL Sia α2-3Gal β1-4GlcNAc 0.69 ± 0.01 0.75 ± 0.01 1.10*** 0.61 ± 0.01 0.56 ± 0.01 0.91**
8 SNAa Sia α2-6Gal/GalNAc 1.01 ± 0.07 0.83 ± 0.03 0.82** 0.94 ± 0.02 0.72 ± 0.04 0.77***
9 SSAa Sia α2-6Gal/GalNAc 0.95 ± 0.02 0.77 ± 0.02 0.81*** 0.94 ± 0.01 0.67 ± 0.01 0.71***
10 TJA-I Sia α2-6Gal/GalNAc 1.98 ± 0.10 1.44 ± 0.10 0.73*** 1.16 ± 0.04 1.38 ± 0.06 1.19***
11 PHA-L Tri/Tetra-antennary complex-type N-glycan 0.62 ± 0.02 0.69 ± 0.01 1.12** 0.58 ± 0.02 0.49 ± 0.01 0.85***
12 ECA Gal β1-4GlcNAc 1.26 ± 0.04 1.22 ± 0.05 0.97* 0.98 ± 0.03 0.99 ± 0.05 1.01
13 RCA120 Gal β1-4GlcNAc 2.36 ± 0.09 1.65 ± 0.12 0.70*** 1.97 ± 0.11 2.47 ± 0.23 1.25***
14 PHA-E Complex-type N-glycans with outer Gal and bisecting GlcNAc 1.11 ± 0.02 1.15 ± 0.03 1.03 1.04 ± 0.05 1.55 ± 0.05 1.50***
15 DSA (GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans 2.57 ± 0.03 2.65 ± 0.09 1.03 1.58 ± 0.06 2.29 ± 0.14 1.45***
16 GSL-II Agalactosylated tri/tetra antennary glycans, GlcNAc 0.43 ± 0.02 0.52 ± 0.02 1.20*** 0.48 ± 0.02 0.31 ± 0.01 0.66***
17 NPAa High Man, Man α1-6Man 1.30 ± 0.02 1.47 ± 0.05 1.13*** 1.29 ± 0.08 1.85 ± 0.14 1.43***
18 ConAa High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc) 1.46 ± 0.08 2.05 ± 0.03 1.40*** 1.93 ± 0.16 2.19 ± 0.15 1.13**
19 GNAa High Man, Man α1-3Man 1.05 ± 0.04 1.12 ± 0.05 1.07*** 0.97 ± 0.04 1.27 ± 0.11 1.30***
20 HHL High Man, Man α1-3Man, Man α1-6Man 0.75 ± 0.02 0.75 ± 0.02 0.99 0.82 ± 0.02 0.76 ± 0.04 0.92*
21 ACG Sia α2-3Gal β1-4GlcNAc 1.45 ± 0.04 1.37 ± 0.07 0.94 1.55 ± 0.06 1.74 ± 0.13 1.12**
22 TxLC-I Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc 0.64 ± 0.02 0.72 ± 0.02 1.13** 0.75 ± 0.02 0.68 ± 0.04 0.90
23 BPLa Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc 0.82 ± 0.02 0.60 ± 0.01 0.73*** 0.58 ± 0.01 0.52 ± 0.03 0.89*
24 TJA-IIa Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals 1.24 ± 0.03 0.89 ± 0.01 0.72*** 1.19 ± 0.06 0.78 ± 0.09 0.65**
25 EEL Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc 0.44 ± 0.02 0.52 ± 0.02 1.17*** 0.41 ± 0.02 0.30 ± 0.02 0.72**
26 ABA Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T 0.86 ± 0.01 0.94 ± 0.01 1.09*** 1.01 ± 0.04 0.94 ± 0.05 0.93*
27 LELa (GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc) 3.22 ± 0.28 3.65 ± 0.14 1.13* 2.37 ± 0.08 3.26 ± 0.18 1.37**
28 STLa (GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone) 2.72 ± 0.21 2.95 ± 0.22 1.09*** 1.48 ± 0.06 2.00 ± 0.13 1.35***
29 UDA GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 1.97 ± 0.22 1.65 ± 0.13 0.84** 1.72 ± 0.06 1.97 ± 0.18 1.14*
30 PWMa (GlcNAc α1-4)n 0.78 ± 0.08 0.52 ± 0.03 0.67*** 0.71 ± 0.03 0.39 ± 0.04 0.54***
31 Jacalin Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 1.02 ± 0.07 1.13 ± 0.08 1.11 1.50 ± 0.05 1.89 ± 0.18 1.25**
32 PNA Gal β1-3GalNAc (α-Thr/Ser (T)) 0.40 ± 0.02 0.41 ± 0.03 1.02 0.62 ± 0.02 0.40 ± 0.02 0.64***
33 WFAa Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc 0.94 ± 0.08 0.59 ± 0.02 0.62*** 0.79 ± 0.03 0.44 ± 0.02 0.55***
34 ACA Gal β1-3GalNAc (α-Thr/Ser (T)) 0.87 ± 0.06 1.21 ± 0.07 1.39*** 1.26 ± 0.05 1.25 ± 0.04 0.99
35 MPA Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 0.61 ± 0.06 0.70 ± 0.06 1.15*** 1.12 ± 0.04 0.58 ± 0.03 0.52***
36 HPA α-Linked terminal GalNAc 0.42 ± 0.04 0.56 ± 0.04 1.33*** 0.74 ± 0.02 0.51 ± 0.05 0.69**
37 VVA α-Linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal 0.46 ± 0.01 0.45 ± 0.02 0.99 0.87 ± 0.05 0.51 ± 0.02 0.58***
38 DBA GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc 0.40 ± 0.01 0.44 ± 0.01 1.11*** 0.61 ± 0.05 0.37 ± 0.02 0.61***
39 SBAa α or β-linked terminal GalNAc, GalNAc α1-3Gal 0.49 ± 0.00 0.42 ± 0.02 0.85** 0.80 ± 0.09 0.53 ± 0.05 0.66***
40 Calsepa High Man (Man2-6), N-glycans including bisecting GlcNAc 0.59 ± 0.01 0.59 ± 0.00 1.01 1.15 ± 0.11 0.90 ± 0.07 0.79**
41 PTL-I α-Linked terminal GalNAc 0.52 ± 0.01 0.51 ± 0.01 0.99 0.75 ± 0.05 0.52 ± 0.04 0.70***
42 MAH Sia α2-3Gal β1-3(Sia α2-6) GalNAc 0.48 ± 0.01 0.52 ± 0.02 1.10* 0.45 ± 0.00 0.37 ± 0.02 0.83**
43 WGA (GlcNAcβ1-4)n, NeuAc, multivalent Sia 1.26 ± 0.01 1.12 ± 0.04 0.89** 1.26 ± 0.03 1.39 ± 0.07 1.11*
44 GSL-IA4 α-GalNAc (α-Thr/Ser (Tn)) 0.39 ± 0.01 0.49 ± 0.01 1.26*** 0.69 ± 0.07 0.37 ± 0.02 0.54**
45 GSL-IB4 α-Gal 0.39 ± 0.01 0.49 ± 0.00 1.25*** 0.87 ± 0.05 0.65 ± 0.03 0.74***
  1. aSignificant changes in the two experiments. * p < 0.05; ** p < 0.01; *** p < 0.001